Celator Pharmaceuticals (Princeton, NI) a clinical-stage small molecule company focused on acute myeloid leukemia and colorectal cancer, closed a $20M Series D financing. Participants have included Thomas McNerney & Partners, BDC Venture Capital, Domain Associates, GrowthWorks Capital, Quaker BioVentures, TL Ventures and Ventures West.